A single institutional clinical outcome for stages III and IV ovarian cancer patients treated with dose‐dense TC therapy in the frontline or first platinum‐sensitive relapse setting

Abstract

AbstractAimDose‐dense paclitaxel /carboplatin (ddTC) therapy was shown to be more effective against ovarian cancer than conventional tri‐weekly TC in the JGOG3016 study. However, two phase III studies performed after JGOG3016 did not show the same positive results. Because we have been using ddTC in the frontline or first platinum‐sensitive relapse of ovarian cancer, we investigated the clinical outcome of the patients treated with ddTC.MethodsWe retrospectively examined the response rate (RR), progression free survival (PFS) and adverse events of the patients who were treated with ddTC for stage III and IV epithelial ovarian, tubal and peritoneal cancer from January 2012 to December 2018.ResultsWe analyzed 50 patients for frontline treatment and 11 patients for first platinum‐sensitive relapse treatment, excluding those receiving maintenance therapy. Among the patients that received frontline ddTC treatment, RR was 82.9% for those in a neo‐adjuvant chemotherapy (NACT) setting and 85.0% for those in an adjuvant setting. The median progression‐free survival (PFS) was 20 months after initial therapy. Among 31 cases that achieved remission by frontline surgery and the following ddTC, 22 had a platinum‐sensitive relapse. RR of 11 patients treated with ddTC therapy alone for the first platinum‐sensitive relapse was 81.8%, and the median PFS of these patients was 22 months after the first recurrence.ConclusionsddTC therapy for advanced ovarian cancer achieved high response rates in all settings (NACT, adjuvant or platinum‐sensitive relapse). ddTC therapy was effective for improving the prognosis of patients with stages III and IV of ovarian cancer.